Mechanism Summary

Dulaglutide is a GLP-1 receptor agonist consisting of a GLP-1 analog fused to a modified human IgG4 Fc fragment, engineered to slow renal clearance and support once-weekly subcutaneous dosing; DrugBank lists its clinical indication as management of type 2 diabetes mellitus.

Pathways

References

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
• https://link.springer.com/article/10.1007/s13300-021-01200-0
• https://go.drugbank.com/drugs/DB09045
• +4 more

Notes

Expansion-batch evidence packet requires human review before publication. | RESOLVED (remediation pass 2026-08-29): Primary REWIND trial publication remained inaccessible directly (Lancet/PubMed/PMC still 403/CAPTCHA-gated this session), but an independent clinical-reference summary (Primary Care Notebook, distinct source family from the packet's Springer secondary review) was fetched and independently corroborates the exact HR 0.88 (95% CI 0.79-0.99, p=0.026), 5.4-year median follow-up, and 9,901-participant population verbatim. Added as a source and cited in extractedEvidence. | RESOLVED (remediation pass 2026-08-29): DOI for the REWIND primary publication (10.1016/S0140-6736(19)31149-3) independently confirmed via Crossref API this session (title/journal/lead-author match REWIND) and added to compound.externalIdentifiers.doi. | STILL OPEN: PubChem CID could not be resolved this remediation session. PUG-REST name and CAS-xref lookups were robots-disallowed; the PubChem compound-summary HTML page was fetched but its 'pubchem_uid_value' meta tag resolved to CID 262 (2,3-Butanediol), which was independently verified via a second fetch to be the WRONG compound - so it was rejected rather than written into the packet. pubchem identifier remains null pending a reliable resolution route (e.g., manual PubChem search UI, or NCBI E-utilities esearch against the PubChem Compound database). | STILL OPEN: dulaglutide-warning-pancreatitis-aki-001 (fieldAuthorityRequired safety-critical claim) remains unresolved. This remediation session attempted: Europe PMC REST API search for 'dulaglutide pancreatitis' (persistently 429 rate-limited across multiple retries with cooldowns, mirroring the original access problem), and PMC full text of Azoulay et al. (incretin drugs/pancreatitis, BMJ 2016) at a candidate PMC ID (410 gone/retired). No independent-family source was reached; the claim stays sourced only to the DailyMed label and remains human-review-gated. Recommend a follow-up attempt via Drugs@FDA safety communications, the FDA/EMA joint pancreatic-safety assessment (NEJM/Cohen 2014), or a fresh Europe PMC query once rate limits clear. | STILL OPEN (partially addressed): dulaglutide-regulatory-approved-indication-001 and dulaglutide-dose-context-label-regimen-001 (both fieldAuthorityRequired) - DrugBank and Wikipedia (independent families) now corroborate the core T2D indication and the dose-tier structure/ceiling respectively, but the CV-indication clause, the no-obesity-indication clause, and the exact 4-week titration interval wording still rest principally on the DailyMed/live-FDA regulator family. ADA Standards of Care (professional.diabetes.org) returned a 403 to the fetch tool again this session. Recommend one further independent-family attempt before final sign-off. | Weight-loss off-label marketing gap is documented from consumer-health media (Healthline) rather than a systematic review of off-label-use prevalence; strength of that characterization should be revisited if a stronger source becomes available. (Note: independent review located a supporting systematic review/meta-analysis - Li et al. 2024, Eur J Clin Invest, DOI 10.1111/eci.14125 - but this remediation session could not itself fetch the Wiley abstract, 403, so it was not added as a verified citation; a future session should re-attempt.) | Compiled draft requires human review before publication.